Skip to content

Clinical Study on the Treatment of Idiopathic Oligoasthenospermia with Bushen Kangle Capsules

Efficacy and Safety of Bushen Kangle Capsules in Idiopathic Oligoasthenospermia: A Clinical Study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000224
Enrollment
Unknown
Registered
2025-02-08
Start date
2025-02-20
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Oligoasthenospermia

Interventions

Experimental group:Levocarnitine+Pancreatic Kininogenase+Bushen Kangle Capsules
Control group:Levocarnitine+Pancreatic Kininogenase

Sponsors

Zhongda Hospital Southeast University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
22 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1) Males aged 22 to 45 years with normal frequency of sexual life in the past year not using contraception and infertile for more than 1 year; (2) Meeting the diagnostic criteria for idiopathic oligoasthenospermia in both traditional Chinese and Western medicine; (3) The serum sex hormone levels of the subjects are within the normal range; (4) The fertility examination of the subjects' female partners is normal; (5) Subjects are capable of understanding and adhering to various steps of the study and have signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Varicocele genital tract obstruction testicular atrophy and other organic factors causing oligoasthenospermia; (2) Azoospermia and severe oligoasthenospermia (sperm concentration upper limit of normal values; (6) Concurrent severe chronic consumptive diseases chronic infectious diseases and psychiatric patients; (7) Working in high-temperature environments patients exposed to radiation; (8) Severe erectile dysfunction or ejaculation disorders affecting fertility; (9) Subjects who have participated in other trials within the past 12 week;

Design outcomes

Primary

MeasureTime frame
Semen analysis;

Secondary

MeasureTime frame
Sperm proteomics;Sex hormone;

Countries

China

Contacts

Public ContactBaofang Jin

Zhongda Hospital Southeast University

hexiking@126.com+86 180 5108 0555

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026